Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ERNA-103
- Development stage
- Preclinical
- Lead developer
- Ernexa Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
01
Overview
ERNA-103 is an allogeneic, off-the-shelf cell therapy candidate being developed by Ernexa Therapeutics for the treatment of solid tumors. The therapy utilizes induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) engineered to deliver a therapeutic payload consisting of interleukin-7 (IL-7), interleukin-15 (IL-15), and C-X-C motif chemokine 9 (CXCL9) directly into the tumor microenvironment. This localized delivery is designed to promote antitumor immune activity, recruit key immune cells, and overcome the immunosuppressive tumor microenvironment of 'cold' tumors, while minimizing systemic toxicity. ERNA-103 is currently in preclinical development.
Beyond the preview
Go deeper on ERNA-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ERNA-103.